Advances in systemic and local therapies are helping more live longer with liver cancer and move forward after treatment as ...

Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver ...

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), ...

After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...

The campaign encourages early detection and inspires the adoption of a healthy lifestyle to prevent liver cancer ...

Merck and Eisai halt late-stage trial as Keytruda/Lenvima combo fails to improve survival in liver cancer. Read more here.

CINCINNATI (WKRC) - As National Liver Awareness Month unfolds, specialists are sounding the alarm on the rising rates of liver disease. A recent survey estimates that as many as seven in 10 people may ...